New RSV vaccine trial aims to protect older adults
NCT ID NCT07582796
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new vaccine against respiratory syncytial virus (RSV) in adults. Phase I includes adults 18 and older to check safety of different doses. Phase II focuses on adults 60 and older to see how well the vaccine triggers an immune response and how safe it is. The vaccine uses a recombinant protein made in CHO cells with an adjuvant to boost immunity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zigong Center for Disease Control and Prevention
RECRUITINGZigong, Sichuan, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••